Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
Xanamem® is being developed as a potential treatment for symptomatic, early stages of
Alzheimer's Disease (AD) and Major Depressive Disorder (MDD).
This XanaMIA Phase 2b study is to investigate the safety, tolerability, and efficacy of
Xanamem in in mild or moderate dementia due to AD. Trial participants will be randomized to
either receive 10mg of Xanamem once daily or a placebo for 36 weeks at a 1:1 ratio in a
double-blinded fashion.